Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew T Roe

Showing results (31-40 of 467) with videos related to

Pageof 47
Sort By:
JAMA|January 7, 2015
Risk profile of clinical trial participants--replyJacob A Udell, Matthew T Roe, Stephen D Wiviott
Clinical Trials (London, England)|November 1, 2016
Maximizing value and minimizing barriers: Patient-centered community consultation for research in emergency settingsChristopher B Fordyce, Matthew T Roe, Neal W Dickert
Drugs|January 27, 2005
Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selectionBrett D Atwater, Matthew T Roe, Kenneth W Mahaffey
Current Cardiology Reports|July 10, 2008
Lessons learned from the CRUSADE National Quality Improvement InitiativeEric D Peterson, David Z Bynum, Matthew T Roe
Annals of Emergency Medicine|February 28, 2003
2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practiceCharles V Pollack, Matthew T Roe, Eric D Peterson
Drugs|June 16, 2021
Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective TreatmentsMatthew T Roe, Bray Patrick-Lake, Andrew C von Eschenbach
American Heart Journal|April 24, 2012
The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarctionDanielle Duffy, Dajuanicia N Holmes, Matthew T Roe, et al.
The American Journal of Cardiology|May 14, 2014
Frequency of nonsystem delays in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention and implications for door-to-balloon time reporting (from the American Heart Association Mission: Lifeline program)David A Cotoni, Matthew T Roe, Shuang Li, et al.
Postgraduate Medicine|July 26, 2008
Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibitionMatthew T Roe, George Kikano, Chadwick D Miller, et al.
The American Journal of Emergency Medicine|August 5, 2003
Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: a local quality improvement initiativeFrancis M Fesmire, Eric D Peterson, Matthew T Roe, et al.
Pageof 47

Showing results (31-40 of 467) with videos related to

Sort By:
Pageof 47
JAMA|January 7, 2015
Risk profile of clinical trial participants--replyJacob A Udell, Matthew T Roe, Stephen D Wiviott
Clinical Trials (London, England)|November 1, 2016
Maximizing value and minimizing barriers: Patient-centered community consultation for research in emergency settingsChristopher B Fordyce, Matthew T Roe, Neal W Dickert
Drugs|January 27, 2005
Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selectionBrett D Atwater, Matthew T Roe, Kenneth W Mahaffey
Current Cardiology Reports|July 10, 2008
Lessons learned from the CRUSADE National Quality Improvement InitiativeEric D Peterson, David Z Bynum, Matthew T Roe
Annals of Emergency Medicine|February 28, 2003
2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practiceCharles V Pollack, Matthew T Roe, Eric D Peterson
Drugs|June 16, 2021
Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective TreatmentsMatthew T Roe, Bray Patrick-Lake, Andrew C von Eschenbach
American Heart Journal|April 24, 2012
The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarctionDanielle Duffy, Dajuanicia N Holmes, Matthew T Roe, et al.
The American Journal of Cardiology|May 14, 2014
Frequency of nonsystem delays in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention and implications for door-to-balloon time reporting (from the American Heart Association Mission: Lifeline program)David A Cotoni, Matthew T Roe, Shuang Li, et al.
Postgraduate Medicine|July 26, 2008
Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibitionMatthew T Roe, George Kikano, Chadwick D Miller, et al.
The American Journal of Emergency Medicine|August 5, 2003
Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: a local quality improvement initiativeFrancis M Fesmire, Eric D Peterson, Matthew T Roe, et al.
Pageof 47